Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Oct
06
Today In Oncology
Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study
ER-Positive HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus
Immune Cell Dysfunction Not Absence Defines Nonmelanoma Skin Cancer in Immunosuppressed Patients
Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer
Global Gaps in Cancer-Control Expenditure Data Identified
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo